Cellectar biosciences stock

Real time CELLECTAR BIOSCIENCES, INC. (CLRBD) stock price quote, stock graph, news & analysis.

Apr 03, 2020 · Cellectar Biosciences has a consensus price target of $6.33, indicating a potential upside of 410.75%. Given Cellectar Biosciences’ higher possible upside, analysts clearly believe Cellectar Biosciences is more favorable than Kadmon. Risk & Volatility. Kadmon has a beta of 1.75, meaning that its stock price is 75% more volatile than the S&P 500. Cellectar Biosciences (CLRB) Stock: An Opportunity After ... If you follow Cellectar Biosciences (NASDAQ: CLRB), you’ve seen a pretty rough few days. In fact, over this period, the stock has given up about 30% of its value. While declines can happen for many reasons, this particular fall in value was unwarranted. Analyzing Kadmon (NYSE:KDMN) and Cellectar Biosciences ...

Cellectar Biosciences, Inc. (CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the 

13 Sep 2019 Roth Capital Partners launched coverage of Cellectar Biosciences (NASDAQ: CLRB) with a “buy” rating and $11 price target. The stock closed  12 Nov 2019 About Cellectar Biosciences, Inc. Cellectar Biosciences is focused on the discovery, development and commercialization of drugs for the  19 Jul 2016 SNNLive spoke with Jim Caruso, President & CEO of Cellectar Biosciences, Inc. ( NASDAQ: CLRB) at the Marcum MicroCap Conference 2016  CLRB Stock Price | Cellectar Biosciences Inc. Stock Quote ... Cellectar Biosciences Inc. Cellectar BioSciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma; CLR 125, which intends to treat micro metastatic disease; Cellectar Biosciences, Inc. Common Stock (CLRB) Stock ...

Transaction Information Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, has closed a sale of 1,982,000 common shares in a registered direct offering and concurrent private placement of 2,018,000 common shares with institutional investors.

CLRB Stock Quote - Cellectar Biosciences, Inc. Common ... Mar 30, 2020 · Stock quote for Cellectar Biosciences, Inc. Common Stock Common Stock (CLRB) with real-time last sale and extended hours stock prices, company news, charts, and research at Nasdaq. ROTH Acts as Sole Placement Agent for Cellectar ... Transaction Information Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, has closed a sale of 1,982,000 common shares in a registered direct offering and concurrent private placement of 2,018,000 common shares with institutional investors. DOCRF vs. CLRB Stock Research Comparison DOCRF (CloudMD Software & Services Inc.) vs. CLRB (Cellectar Biosciences, Inc.) stock comparison side-by-side research /w SpeculatingStocks FREE tool. CLRB - Cellectar Biosciences Inc Stock quote - CNNMoney.com

Product Pipeline :: Cellectar Biosciences, Inc. (CLRB)

Stock analysis for Cellectar Biosciences Inc (CLRB:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company  The Cellectar Biosciences stock price is 1.190 USD today. Will Cellectar Biosciences stock price grow / rise / go up? Yes. The CLRB stock price can go up from  25 Feb 2020 If you follow Cellectar Biosciences (NASDAQ: CLRB), you've seen a pretty rough few days. In fact, over this period, the stock has given up  In depth view into CLRB (Cellectar Biosciences) stock including the latest price, news, dividend history, earnings information and financials.

Discover historical prices for CLRB stock on Yahoo Finance. View daily, weekly or monthly format back to when Cellectar Biosciences, Inc. stock was issued.

Cellectar Biosciences, Inc. (CLRB) Stock Analysis & News ...

The 3 analysts offering 12-month price forecasts for Cellectar Biosciences Inc have a median target of 6.40, with a high estimate of 10.00 and a low estimate of